Skip to main content
NCBI home page
Gut logoLink to Gut
. 1994 Mar;35(3):360–362. doi: 10.1136/gut.35.3.360

Frequency of glucocorticoid resistance and dependency in Crohn's disease.

P Munkholm 1, E Langholz 1, M Davidsen 1, V Binder 1
PMCID: PMC1374590  PMID: 8150347

Abstract

The outcome of the first steroid treatment course was prospectively studied in a regional cohort of 196 patients with Crohn's disease diagnosed 1979-1987. The immediate outcome after 30 days, and the prolonged outcome 30 days after treatment had stopped, are described. In all 109 patients treatment was analysed. Complete remission was obtained in 48%, partial remission in 32%, and no response in 20% within 30 days of treatment. Among primary responders (complete and partial remission), 55% remained in prolonged response after treatment had finished, while 45% relapsed or could not be withdrawn from treatment within one year. Localisation of disease, age, sex or clinical symptoms did not significantly correlate with outcome, which can be summarised as prolonged steroid response in 44%, steroid dependency in 36%, and steroid resistant in 20% of the patients.

Full text

PDF
360

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brattsand R., Thalén A., Roempke K., Källström L., Gruvstad E. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. Eur J Respir Dis Suppl. 1982;122:62–73. [PubMed] [Google Scholar]
  2. Edsbäcker S., Jönsson S., Lindberg C., Ryrfeldt A., Thalén A. Metabolic pathways of the topical glucocorticoid budesonide in man. Drug Metab Dispos. 1983 Nov-Dec;11(6):590–596. [PubMed] [Google Scholar]
  3. Lennard-Jones J. E. Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease. Gut. 1983 Mar;24(3):177–181. doi: 10.1136/gut.24.3.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Malchow H., Ewe K., Brandes J. W., Goebell H., Ehms H., Sommer H., Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984 Feb;86(2):249–266. [PubMed] [Google Scholar]
  5. Modigliani R., Mary J. Y., Simon J. F., Cortot A., Soule J. C., Gendre J. P., Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990 Apr;98(4):811–818. doi: 10.1016/0016-5085(90)90002-i. [DOI] [PubMed] [Google Scholar]
  6. Munkholm P., Langholz E., Nielsen O. H., Kreiner S., Binder V. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol. 1992 Jul;27(7):609–614. doi: 10.3109/00365529209000127. [DOI] [PubMed] [Google Scholar]
  7. Singleton J. W., Law D. H., Kelley M. L., Jr, Mekhjian H. S., Sturdevant R. A. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology. 1979 Oct;77(4 Pt 2):870–882. [PubMed] [Google Scholar]
  8. Summers R. W., Switz D. M., Sessions J. T., Jr, Becktel J. M., Best W. R., Kern F., Jr, Singleton J. W. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979 Oct;77(4 Pt 2):847–869. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES